Value
5.4/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 0.0 |
| Analyst target | 9.0 |
NRIX · Why this verdict
Why Nurix Therapeutics (NRIX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.3/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Nurix Therapeutics is a cash-burning clinical-stage biotechnology company heavily dependent on its bexobrutideg program, with a high short interest of 19% and a quality score of 1.8 far below acceptable thresholds, but recent analyst cluster activity and 63.7% upside to consensus target reflect speculative event-driven interest.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The company's investment thesis is almost entirely dependent on the bexobrutideg program, creating a binary risk profile where trial success or failure will dominate stock performance. Bear case | Clinical milestone announcements for bexobrutideg over the next 12 months provide observable catalysts that either validate or invalidate the core thesis. | →Stable |
| CounterConcentration in a single program is standard for a development-stage biotech of this size; analysts covering the stock have maintained upside targets suggesting they view the program favorably. | ||
A cluster of 3 analyst events was recently detected in the news, which has historically been associated with increased institutional attention and can precede coverage initiations or rating upgrades. Bull case | Analyst coverage expands beyond the current base and at least 1 new initiation or price target increase occurs within 12 months. | →Stable |
| CounterAnalyst attention alone does not create fundamental value; prior earnings record is split 2 beats and 2 misses on EPS, indicating execution uncertainty. | ||
Nurix burns cash at 203% of revenue, has a Piotroski F-Score of only 3/9, and its quality score of 1.8 is far below the minimum acceptable threshold, signaling serious business health concerns. Quality breakdown | Cash burn rate as a percentage of revenue declines below 150% within 12 months as the company moves programs toward later-stage development. | →Stable |
| CounterCash burning is expected and appropriate for a clinical-stage biotech; the current ratio score of 7.0 suggests the balance sheet can fund operations near-term. | ||
Short interest stands at 19% of the float and the put/call ratio is 4.62, indicating that a significant portion of the market is positioned against this stock and expects further downside. Key risks | Short interest falls below 12% and put/call ratio declines below 2.5 over the next 12 months as catalyst uncertainty resolves. | →Stable |
| CounterHigh short interest can create a short squeeze dynamic if positive clinical news surprises the market, amplifying any upside move; options market reflects speculation, not certainty. | ||
The company's investment thesis is almost entirely dependent on the bexobrutideg program, creating a binary risk profile where trial success or failure will dominate stock performance.
→StableBear case
- Expectation
- Clinical milestone announcements for bexobrutideg over the next 12 months provide observable catalysts that either validate or invalidate the core thesis.
CounterConcentration in a single program is standard for a development-stage biotech of this size; analysts covering the stock have maintained upside targets suggesting they view the program favorably.
A cluster of 3 analyst events was recently detected in the news, which has historically been associated with increased institutional attention and can precede coverage initiations or rating upgrades.
→StableBull case
- Expectation
- Analyst coverage expands beyond the current base and at least 1 new initiation or price target increase occurs within 12 months.
CounterAnalyst attention alone does not create fundamental value; prior earnings record is split 2 beats and 2 misses on EPS, indicating execution uncertainty.
Nurix burns cash at 203% of revenue, has a Piotroski F-Score of only 3/9, and its quality score of 1.8 is far below the minimum acceptable threshold, signaling serious business health concerns.
→StableQuality breakdown
- Expectation
- Cash burn rate as a percentage of revenue declines below 150% within 12 months as the company moves programs toward later-stage development.
CounterCash burning is expected and appropriate for a clinical-stage biotech; the current ratio score of 7.0 suggests the balance sheet can fund operations near-term.
Short interest stands at 19% of the float and the put/call ratio is 4.62, indicating that a significant portion of the market is positioned against this stock and expects further downside.
→StableKey risks
- Expectation
- Short interest falls below 12% and put/call ratio declines below 2.5 over the next 12 months as catalyst uncertainty resolves.
CounterHigh short interest can create a short squeeze dynamic if positive clinical news surprises the market, amplifying any upside move; options market reflects speculation, not certainty.
Per-dimension breakdown
Quality
1.8/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 7.0 |
| FCF quality | 0.0 |
| Moat | 4.0 |
| Piotroski F | 3.3 |
- ▸Cash-burning: FCF -203% of revenue
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 3/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
6.5/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.6 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Overbought (RSI 88)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.9/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 8.7 |
| Price target | 9.4 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 47%
Insider
3.8/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 5.0 |
- ▸Modest insider selling — $868,082 (0.043% of mkt cap)
Peer rank
1.1/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 1.8 |
| quality rank | 1.4 |
| growth rank | 1.3 |
Technical
3.0/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.1 |
| 52w position | 9.0 |
Risk (lower is worse)
3.6/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.6 |
| days to cover | 0.0 |
| volatility | 0.0 |
| put call | 6.8 |
| implied vol | 0.0 |
| max pain risk | 7.0 |
| beta | 3.8 |
| debt equity | 9.5 |
- ▸High short interest justified: 19%
- ▸High IV: 115%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
4.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 4.6 |
- ▸Earnings concerns: 2B/2M
- ▸Earnings in 14 days
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:6.5>=5.5
- ASYMMETRY:2.2>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (1)
- EARNINGS_PROXIMITY:14d<=14d (soft)
Reward-to-Risk
2.16
Upside
+32.5%
Downside
15.0%
Sizing output
AVOID
SetupUNKNOWN — No clear chart pattern; technical signals are mixed
EdgeNO_EDGE — No clear edge identified
SuitabilityAGGRESSIVE — Beta 1.87>1.3, MCap $2.0B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Sentiment at 7.9 could not lift the engine output above the verdict floor.
The strongest dimensions are Sentiment at 7.9, Momentum at 6.5, and Value at 5.4; the weakest are Peer rank at 1.1, Quality at 1.8, and Technical at 3.0. The V9 engine cleared all gates with 1 warning, producing an asymmetric reward-to-risk of 2.16 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1The company's investment thesis is almost entirely dependent on the bexobrutideg program, creating a binary risk profile where trial success or failure will dominate stock performance.
Trip ifA clinical hold or program termination on bexobrutideg is announced, causing the stock to fall below $12.
- P2A cluster of 3 analyst events was recently detected in the news, which has historically been associated with increased institutional attention and can precede coverage initiations or rating upgrades.
Trip ifAnalyst coverage falls below 3 active analysts or consensus price target declines below $20.
- P3Nurix burns cash at 203% of revenue, has a Piotroski F-Score of only 3/9, and its quality score of 1.8 is far below the minimum acceptable threshold, signaling serious business health concerns.
Trip ifCash burn rate increases above 250% of revenue for 2 consecutive quarters.
- P4Short interest stands at 19% of the float and the put/call ratio is 4.62, indicating that a significant portion of the market is positioned against this stock and expects further downside.
Trip ifShort interest rises above 25% or put/call ratio exceeds 6.0.